Table 2.
Clinical features of newly discovered patients with anti-AMPAR antibodies, screened with AMPAR subdomain fusion proteins on western blot.
| Case no. | Sex/age (year) | Symptom presentation | Evidence of immune involvement? | Main GluA subdomain reactivity |
|---|---|---|---|---|
| 1 | F/42 | Six month history of altered mental status (memory, behavior, verbal fluency) | Anti-thyroid antibodies | GluA2-all domains (CSF) |
| 2 | M/77 | Convulsions, memory loss, amnesia, limbic encephalitis | None | GluA1-S2 (CSF); GluA1- ATD, top lobe (serum) |
| 3 | M/62 | Convulsions, memory loss, amnesia, auditory hallucinations, limbic encephalitis | None | GluA1-S2 (serum) |
| 4 | M/30 | Convulsions, memory loss, amnesia, abnormal behavior | None | GluA1-S2 (serum) |
| 5 | M/43 | Mental status change | Improved with immunotherapy | GluA2-S1 (serum) |
| 6 | Limbic encephalitis | None | GluA1-S2 (serum) | |
| 7 | F/60 | Seizures, short-term memory loss, limbic encephalitis | None | GluA2-ATD, top lobe (serum) |
| 8 | F/23 | Schizophrenia, seizures | None | GluA1-S2, top lobe (serum) |
| 9 | F/55 | Schizophrenia, seizures | None | GluA1-S2 (serum) |
| 10 | F/7 | Memory loss, limbic encephalitis | CSF: 57 WBCs | GluA2-top lobe (serum) |
| 11 | F/78 | Encephalitis with increasing memory loss | None | GluA2-ATD, top lobe (serum) |
| 12 | F/37 | Altered mental status, encephalitis | Herpes encephalitis | GluA2-ATD, top, bottom, S2 (serum) |
| 13 | M/8 | Seizures, status epilepticus | None | GluA2-ATD (serum) |
| 14 | M/28 | Dizziness, ataxia, hyperthermia | CSF: 8 WBCs | GluA1-S2 (serum) |
| 15 | M/27 | Chorea, facial dyskinesia | CSF: 12 WBCs, onset with flu-like symptoms | GluA2-ATD (serum) |
IgG isolated from serum of patient 5 was used in electrophysiological experiments.